



CEE UPDATES

September 2026



NEW TERM OF THE ACE CONSUMER PANEL



Find out more



A new term of the ACE Consumer Panel began on 1 April 2026, bringing together patient engagement leaders from local patient organisations, the healthcare clusters and academic institutions. The Panel held its first meeting of the new term in May, and we look forward to working with the Panel over the next two years to strengthen patient involvement in ACE's work and other Ministry of Health (MOH) initiatives supported by ACE.



ANNUAL CALL FOR TOPICS IS OPEN!



ACE conducts technical evaluations to assess the effectiveness, safety, and value of health technologies (such as drugs, vaccines, and medical devices) to inform the Ministry of Health (MOH) advisory committees' funding recommendations.

The **annual call for topics** is open for patients, carers and patient organisations to suggest which health technologies they would like ACE to evaluate for different health conditions. Read our [factsheet](#) to find out the key steps of the application process.

Topic suggestions should be submitted by **13 November 2026**. Contact the CEE team or your patient organisation for an application form.



PATIENT GLOSSARY UPDATED



Find out more



Explore ACE's Updated Patient Glossary



Have you ever come across a word in one of ACE's educational resources that you were unfamiliar with? Our **Patient Glossary** provides simple, easy-to-understand definitions of healthcare and technical words commonly used in our resources, helping patients and carers better understand the information we provide. The glossary is periodically updated to include new terms and keep the definitions relevant and useful.

SHOWCASING SINGAPORE'S PATIENT INVOLVEMENT INITIATIVES THROUGH CONFERENCES AND EVENTS

Singapore Primary Care Conference, 15 to 16 May 2026



The CEE team participated in ACE's booth at the conference, highlighting ACE's patient education resources and learning modules alongside other key areas of ACE's work. This provided an opportunity for us to engage and share our work with primary care professionals from across Singapore and the region.

13th HTAsiaLink Conference 2026, 1 to 4 September 2026



At a pre-conference workshop led by the HTAi Patient and Citizen Involvement in HTA Interest Group (PCIG) titled "**Asia Pacific 360: Strengthening patient involvement in HTA across our region**", the CEE team presented findings from the Asia Pacific 360 study alongside patient leaders from across the region, and shared Singapore's experience as a practical example. The workshop brought together different perspectives on patient involvement in HTA and included facilitated discussions on opportunities to strengthen approaches across Asia Pacific.


During the main conference, the CEE team delivered an oral presentation of the accepted abstract, "Using Patient Perspectives in Health Technology Assessment for Rare Conditions: A Singapore Case Study". The presentation materials are available on the [ACE website](#).

4

Patient factsheets published since May 2026

- Injectable treatments for severe asthma (new)
- Biosimilars: A safe, effective and more affordable option for patients (updated)
- Oral treatments for blood clots (updated)
- Treatments for Crohn's disease and ulcerative colitis (updated)

NEW



Find out more



PLAIN ENGLISH SUMMARIES


11

Plain English summaries published since July 2026

Plain English summaries (PES) provide a brief overview of the health technologies and conditions that have been evaluated by ACE, and the key funding recommendations made by the MOH advisory committees.

PES are now available directly on the webpage of each technology guidance.

NEW



Find out more



New:

- Belzutifan for von Hippel-Lindau disease with associated non-metastatic renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumours
- Biologics as add-on therapy for treating chronic rhinosinusitis with nasal polyps
- Elacestrant for ER-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation
- Enfortumab vedotin in combination with pembrolizumab for untreated locally advanced or metastatic urothelial cancer
- Glofitamab for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in patients who are not candidates for autologous stem cell transplant
- Maribavir for treating refractory or drug-intolerant cytomegalovirus infection after transplant
- Nirsevimab for prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants during their first RSV season
- Vutrisiran for transthyretin amyloid cardiomyopathy

Updated:

- Disease-modifying therapies for treating multiple sclerosis
- Eplontersen and vutrisiran for treating hereditary transthyretin amyloidosis with polyneuropathy
- Zolbetuximab for untreated HER2-negative, claudin-18.2-positive, unresectable advanced gastric or gastroesophageal junction adenocarcinoma

PATIENT INPUT

Over

40

Patient responses were gathered for topics presented to the MOH advisory committees in April 2026

The effort put in by patients and carers to share their experiences is appreciated and every input is valuable to ACE and MOH. The CEE team notifies patient organisations of the advisory committees' funding recommendations after each meeting and provides feedback on which information provided was most helpful to the committees' deliberations.



OTHER PATIENT INVOLVEMENT ACTIVITIES



Advancing Patient and Public Involvement in Asia - Research with the People, for the People 5 and 19 August 2026

Fiona Pearce (ACE Senior Advisor; Chair of HTAi Patient and Citizen Involvement in HTA Interest Group [PCIG]) presented in an online plenary and roundtable on strengthening meaningful patient and public involvement (PPI) in medical research, organised by the International PPI Network (IPPIN) and the Office of Patient Engagement (OPEN), Lee Kong Chian School of Medicine, Nanyang Technological University. ACE Consumer Panel Chair Ellil Mathiyen Lakshmanan (Ostomy Association of Singapore) and Panel member Ai Ling Sim-Devadas (OPEN) were also among the speakers. The recording is available online [here](#).

A follow-up session was held to build on insights from the online roundtable, with participants discussing the challenges and opportunities for PPI in research in Asia, and ways to strengthen meaningful involvement across the region. A written commentary of key insights from both roundtables will be published soon. Stay tuned!



The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidelines and education.

The Consumer Engagement and Education (CEE) team supports patient involvement in ACE's work and co-develops plain English summaries and educational resources with patient organisations to improve health literacy and encourage shared healthcare decision-making between patients and their doctors.

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore.

Published on 28 September 2026 To find out more about ACE, scan the QR code or visit www.ace-hta.gov.sg. You can also follow us on social media at:

